$EYPT
EyePoint Pharmaceuticals, Inc.

2018 Q3 Form 10-K Financial Statement

#000119312518276414 Filed on September 18, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2018
Revenue $486.0K $715.0K $4.571M
YoY Change 26.23% 2.0% -39.37%
Cost Of Revenue $0.00
YoY Change
Gross Profit $715.0K
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $7.807M $5.732M $25.09M
YoY Change 203.54% 118.78% 123.3%
% of Gross Profit 801.68%
Research & Development $6.233M $4.765M $18.50M
YoY Change 63.21% 13.18% 24.34%
% of Gross Profit 666.43%
Depreciation & Amortization $43.00K $650.0K $167.0K
YoY Change 10.26% 209.52% 83.52%
% of Gross Profit 90.91%
Operating Expenses $14.04M $10.50M $43.59M
YoY Change 119.68% 53.46% 66.92%
Operating Profit -$13.55M -$9.782M -$39.02M
YoY Change 125.67% 59.42% 110.05%
Interest Expense $815.0K $720.0K $2.362M
YoY Change 3500.0%
% of Operating Profit
Other Income/Expense, Net -$19.57M -$24.65M $420.0K
YoY Change -85195.65% 361.54%
Pretax Income -$33.13M -$34.43M -$53.17M
YoY Change 454.01% 462.58% 187.64%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$33.13M -$34.43M -$86.13M
YoY Change 453.67% 462.92% 365.92%
Net Earnings / Revenue -6816.05% -4815.1% -1884.16%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.406M -$6.215M -$5.255M
COMMON SHARES
Basic Shares Outstanding 74.51M shares 54.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.80M $38.80M $45.30M
YoY Change 372.88% 129.59% 168.05%
Cash & Equivalents $55.76M $38.78M $45.30M
Short-Term Investments
Other Short-Term Assets $1.400M $800.0K $1.400M
YoY Change 250.0% 33.33% 133.33%
Inventory $300.0K
Prepaid Expenses
Receivables $500.0K $400.0K $600.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $57.64M $39.91M $47.60M
YoY Change 359.41% 124.97% 168.93%
LONG-TERM ASSETS
Property, Plant & Equipment $320.0K $253.0K $300.0K
YoY Change -5.04% -19.17% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $200.0K $200.0K
YoY Change -33.33% -33.33% -33.33%
Total Long-Term Assets $31.21M $31.76M $30.60M
YoY Change 3901.67% 3289.65% 2960.0%
TOTAL ASSETS
Total Short-Term Assets $57.64M $39.91M $47.60M
Total Long-Term Assets $31.21M $31.76M $30.60M
Total Assets $88.86M $71.67M $78.20M
YoY Change 566.73% 283.73% 318.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.075M $2.940M $2.600M
YoY Change 132.06% 189.37% 160.0%
Accrued Expenses $3.343M $3.723M $18.80M
YoY Change 33.03% -11.86% 347.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.42M $21.66M $21.50M
YoY Change 423.91% 309.51% 305.66%
LONG-TERM LIABILITIES
Long-Term Debt $17.46M $17.31M $17.60M
YoY Change
Other Long-Term Liabilities $1.269M $1.231M $1.500M
YoY Change 2313.73% 1400.0%
Total Long-Term Liabilities $18.73M $18.54M $19.10M
YoY Change 36252.94% 19000.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.42M $21.66M $21.50M
Total Long-Term Liabilities $18.73M $18.54M $19.10M
Total Liabilities $41.15M $59.98M $40.50M
YoY Change 851.23% 1023.07% 664.15%
SHAREHOLDERS EQUITY
Retained Earnings -$396.9M -$364.0M
YoY Change 25.28% 17.11%
Common Stock $443.8M $374.8M
YoY Change 36.56% 15.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.71M $11.69M $37.60M
YoY Change
Total Liabilities & Shareholders Equity $88.86M $71.67M $78.20M
YoY Change 566.73% 283.73% 318.18%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2018
OPERATING ACTIVITIES
Net Income -$33.13M -$34.43M -$86.13M
YoY Change 453.67% 462.92% 365.92%
Depreciation, Depletion And Amortization $43.00K $650.0K $167.0K
YoY Change 10.26% 209.52% 83.52%
Cash From Operating Activities -$11.77M -$6.080M -$21.91M
YoY Change 97.15% 36.63% 6.92%
INVESTING ACTIVITIES
Capital Expenditures $109.0K -$50.00K $108.0K
YoY Change 70.31% -61.54% -26.53%
Acquisitions $16.78M
YoY Change
Other Investing Activities -$1.710M $0.00
YoY Change -168.4% -100.0%
Cash From Investing Activities -$109.0K -$1.750M -$16.89M
YoY Change 70.31% -173.53% -224.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.90M $41.52M
YoY Change 2901.04% 393.99%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 28.86M 30.26M 60.67M
YoY Change 2897.2% 396.07% 613.52%
NET CHANGE
Cash From Operating Activities -11.77M -6.080M -21.91M
Cash From Investing Activities -109.0K -1.750M -16.89M
Cash From Financing Activities 28.86M 30.26M 60.67M
Net Change In Cash 16.99M 22.43M 21.88M
YoY Change -435.4% 456.58% 1280.32%
FREE CASH FLOW
Cash From Operating Activities -$11.77M -$6.080M -$21.91M
Capital Expenditures $109.0K -$50.00K $108.0K
Free Cash Flow -$11.88M -$6.030M -$22.02M
YoY Change 96.87% 39.58% 6.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q4 dei Entity Public Float
EntityPublicFloat
48816000
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
74512048 shares
CY2017Q4 us-gaap Share Price
SharePrice
1.045
CY2015Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19271000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
23368000
CY2016Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.50
CY2016Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15463000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
623605 shares
CY2016Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
0
CY2016Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
35094000
CY2016Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
36196000
CY2016Q2 us-gaap Restructuring Reserve
RestructuringReserve
187000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
20881000
CY2016Q2 eypt Accrued Development Milestone Current
AccruedDevelopmentMilestoneCurrent
0
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4224000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
17740000
CY2017Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
251000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
590000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
486000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
323284000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1016000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
833000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
833000
CY2017Q2 us-gaap Assets
Assets
18677000
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
0
CY2017Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
0
CY2017Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.50
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16898000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17048000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39356999 shares
CY2017Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
623605 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39356999 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
39000
CY2017Q2 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
0
CY2017Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
0
CY2017Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
20000
CY2017Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
186000
CY2017Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46356000
CY2017Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
123000
CY2017Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
39439000
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
50000
CY2017Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46479000
CY2017Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2017Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1727000
CY2017Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5107000
CY2017Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
35246000
CY2017Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
35610000
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
364000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5290000
CY2017Q2 us-gaap Liabilities
Liabilities
5341000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18677000
CY2017Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18000
CY2017Q2 us-gaap Other Assets
OtherAssets
110000
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
313000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
591000
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2017Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
799000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-310820000
CY2017Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
13336000
CY2017Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q2 eypt Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
46356000
CY2017Q2 eypt Accrued Interest Payable Current
AccruedInterestPayableCurrent
0
CY2017Q2 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
1984000
CY2017Q2 eypt Accrued Development Milestone Current
AccruedDevelopmentMilestoneCurrent
0
CY2017Q2 eypt Employeerelated Accrued Liabilities Current
EmployeerelatedAccruedLiabilitiesCurrent
1632000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3723000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
39909000
CY2018Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
353000
CY2018Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
926000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
653000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
374766000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2940000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
838000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
838000
CY2018Q2 us-gaap Assets
Assets
71670000
CY2018Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
0
CY2018Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
0
CY2018Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.23
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38776000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38926000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
74512048 shares
CY2018Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
486812 shares
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74512048 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
74000
CY2018Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
1200000
CY2018Q2 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
0
CY2018Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
185000
CY2018Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47121000
CY2018Q2 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
8542000
CY2018Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47774000
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2018Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55663000
CY2018Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
19780000
CY2018Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3463000
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4241000
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
5400000
CY2018Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
36964000
CY2018Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
68322000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
31358000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
21663000
CY2018Q2 us-gaap Liabilities
Liabilities
59983000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71670000
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17309000
CY2018Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
28800000
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38000
CY2018Q2 us-gaap Other Assets
OtherAssets
0
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
886000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5520000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
870000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
548000
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
892000
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1231000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
253000
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
780000
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
150000
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
906000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-363991000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
11687000
CY2018Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q2 eypt Deferred Tax Assets Liabilities Net Before Valuation Allowance
DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
47121000
CY2018Q2 eypt Accrued Interest Payable Current
AccruedInterestPayableCurrent
254000
CY2018Q2 eypt Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
742000
CY2018Q2 eypt Operating Leases Future Minimum Payments Due In Year Five And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInYearFiveAndThereafter
2324000
CY2018Q2 eypt Accrued Development Milestone Current
AccruedDevelopmentMilestoneCurrent
15000000
CY2018Q2 eypt Employeerelated Accrued Liabilities Current
EmployeerelatedAccruedLiabilitiesCurrent
1763000
CY2017Q4 eypt Retention Bonus Paid Under Agreements
RetentionBonusPaidUnderAgreements
319000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34 pure
CY2017Q1 eypt Legal Accounting And Other Fees
LegalAccountingAndOtherFees
223000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2456000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8677790 shares
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-9000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2456000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
724000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1585000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18504000
CY2017 us-gaap Depreciation
Depreciation
91000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000
CY2017 us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
-586000
CY2017 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2017 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
0
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11235000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17566000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18485000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-919000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-346000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
99000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6284000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
242000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-97000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
7489000
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-121000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-928000
CY2017 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-219000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
95000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
650000
CY2017 us-gaap Interest Expense
InterestExpense
0
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
18743000
CY2017 us-gaap Profit Loss
ProfitLoss
-18485000
CY2017 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
5585000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
0
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13577000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8503000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20490000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-18485000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
91000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-21000
CY2017 us-gaap Operating Expenses
OperatingExpenses
26115000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-18576000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
442000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2017 us-gaap Payments For Restructuring
PaymentsForRestructuring
659000
CY2017 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2017 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5052000
CY2017 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
147000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8404000
CY2017 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
33000
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
99000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14880000
CY2017 us-gaap Restructuring Charges
RestructuringCharges
472000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7539000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2456000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8404000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
99000
CY2017 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
0
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35344000 shares
CY2017 eypt Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
-9000
CY2017 eypt Finite Lived Intangible Assets Foreign Currency Translation Of Accumulated Amortization
FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization
-572000
CY2017 eypt Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-9000
CY2017 eypt Income Tax Reconciliation Change In Fair Value Of Derivative Liability
IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability
0
CY2017 eypt Amortization Of Debt Discount
AmortizationOfDebtDiscount
0
CY2017 eypt Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
193000
CY2017 eypt Fair Value Of Warrants Issued With Debt
FairValueOfWarrantsIssuedWithDebt
0
CY2017 eypt Fair Value Of Second Tranche Purchase Liability
FairValueOfSecondTranchePurchaseLiability
0
CY2017 eypt Warrants To Purchase Common Shares Expired
WarrantsToPurchaseCommonSharesExpired
0 shares
CY2017 eypt Warrants Issued In Connection With Term Loan Facility
WarrantsIssuedInConnectionWithTermLoanFacility
0 shares
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
981000
CY2017 eypt Exercise Price Of Expired Warrants
ExercisePriceOfExpiredWarrants
0.00
CY2017 eypt Exercise Price Of Issued Warrants
ExercisePriceOfIssuedWarrants
0.00
CY2017 eypt Fair Value Of Second Tranche Warrants
FairValueOfSecondTrancheWarrants
0
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
355000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2704000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30321078 shares
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2704000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentrations of Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. At June&#xA0;30, 2018, a total of $28.8&#xA0;million, representing all of the Company&#x2019;s interest-bearing cash equivalent balances, were concentrated in one U.S. Government institutional money market fund that had investments consisting primarily of U.S. Government Agency debt, U.S. Treasury Repurchase Agreements and U.S. Government Agency Repurchase Agreements. Generally, these deposits may be redeemed upon demand and, therefore, the Company believes they have minimal risk. The Company had no investments in marketable securities at June&#xA0;30, 2018 and 2017. The Company&#x2019;s investment policy, approved by the Company&#x2019;s Board of Directors, includes guidelines relative to diversification and maturities designed to preserve principal and liquidity.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Revenues from Alimera accounted for $723,000, or 24% of total revenues in fiscal 2018, $659,000, or 9% of total revenues in fiscal 2017 and $233,000, or 14% of total revenues in fiscal 2016. Revenues from Pfizer accounted for $5.6&#xA0;million, or 74% of total revenues in fiscal 2017 and were inconsequential in fiscal 2018 and fiscal 2016. Revenues from Bausch&#xA0;&amp; Lomb accounted for approximately $1.0&#xA0;million, or 35% of total revenues in fiscal 2018, $984,000, or 13% of total revenues in fiscal 2017 and $1.3&#xA0;million, or 77% of total revenues in fiscal 2016. Revenues from feasibility study agreements accounted for approximately $1.1&#xA0;million, or 37% of total revenues in fiscal 2018, $211,000, or 3%, of total revenues in fiscal 2017 and were inconsequential in fiscal 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Accounts receivable from Bausch&#xA0;&amp; Lomb accounted for $306,000, or 87% of total accounts receivable at June&#xA0;30, 2018 and $246,000, or 98%, of total accounts receivable at June&#xA0;30, 2017.</p> </div>
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21878000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53166000
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2018 us-gaap Depreciation
Depreciation
167000
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Type
DocumentType
10-K
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05 pure
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.275 pure
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001314102
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2018 dei Entity Registrant Name
EntityRegistrantName
EyePoint Pharmaceuticals, Inc.
CY2018 us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
739000
CY2018 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
31973000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11545000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-53000000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53171000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-171000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
14673000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1747000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
174000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14622000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
284000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-50000
CY2018 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-26278000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-5385000
CY2018 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-66000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1552000
CY2018 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-7000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
24000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-585000
CY2018 us-gaap Interest Expense
InterestExpense
720000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
258000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> </p> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr style="break-inside: avoid"> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt" align="left"><b>Operations</b></p> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> EyePoint Pharmaceuticals, Inc. (together with its subsidiaries, the &#x201C;Company&#x201D;), incorporated in Delaware, is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases. The Company&#x2019;s lead product, DEXYCU&#x2122; (dexamethasone intraocular suspension) 9%, approved by the United States (&#x201C;U.S.&#x201D;) Food and Drug Administration (&#x201C;FDA&#x201D;) in February 2018 for the treatment of post-operative inflammation, is administered as a single dose at the end of ocular surgery and is the first long-acting intraocular product approved by the FDA for the treatment of post-operative inflammation. DEXYCU utilizes the Company&#x2019;s proprietary Verisome<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;drug-delivery platform, which allows for a single intraocular injection that releases dexamethasone, a corticosteroid, over time. There are approximately four million cataract surgeries performed annually in the U.S. and the Company plans to launch DEXYCU in the U.S. in the first half of calendar year 2019 with a primary focus on its use following cataract surgery. The Company acquired DEXYCU in connection with its acquisition of Icon Bioscience, Inc. (&#x201C;Icon&#x201D;) in March 2018. The Company&#x2019;s lead product candidate is YUTIQ&#x2122;, a three-year&#xA0;<font style="WHITE-SPACE: nowrap">non-erodible</font>&#xA0;fluocinolone acetonide insert for the treatment of&#xA0;<font style="WHITE-SPACE: nowrap">non-infectious</font>&#xA0;posterior uveitis (&#x201C;NIPU&#x201D;). Injected into the eye in an office visit, YUTIQ is a tiny micro-insert that delivers a micro-dose of a corticosteroid to the back of the eye on a sustained constant (zero order release) basis for approximately three years. On March&#xA0;19, 2018, the FDA accepted the Company&#x2019;s New Drug Application (&#x201C;NDA&#x201D;) for YUTIQ and set an FDA Prescription Drug User Fee Act (&#x201C;PDUFA&#x201D;) action date of November&#xA0;5, 2018. YUTIQ is based on the Company&#x2019;s proprietary Durasert&#x2122; sustained-release drug delivery technology platform, which can deliver drugs for predetermined periods of time ranging from months to years. Posterior segment uveitis is the third leading cause of blindness in the U.S. and affects between 55,000 to 120,000 people. If approved in November 2018, the Company expects to launch YUTIQ in the first half of calendar year 2019.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> ILUVIEN<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;for diabetic macular edema (&#x201C;DME&#x201D;), the Company&#x2019;s lead licensed product, is sold directly in the U.S. and several European Union (&#x201C;EU&#x201D;) countries by Alimera Sciences, Inc. (&#x201C;Alimera&#x201D;). Retisert<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>, one of the Company&#x2019;s earlier generation products, was approved in 2005 by the FDA for the treatment of posterior segment uveitis and is sold in the U.S. by Bausch&#xA0;&amp; Lomb Incorporated (&#x201C;Bausch&#xA0;&amp; Lomb&#x201D;). The Company&#x2019;s development programs are focused primarily on developing sustained release products that utilize its Durasert and Verisome technology platforms to deliver approved drugs to treat chronic diseases. The Company&#x2019;s strategy includes developing products independently while continuing to leverage its technology platforms through collaborations and license agreements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-ligatures: normal; font-variant-caps: normal"> The Company has financed its operations primarily from sales of equity securities, debt and the receipt of license fees, milestone payments, research and development funding and royalty income from its collaboration partners. The Company has a history of operating losses and, to date, has not had significant recurring cash inflows from revenue. The Company&#x2019;s anticipated recurring use of cash to fund operations, in combination with no probable source of additional capital, raises substantial doubt about its ability to continue as a going concern for one year from the issuance of its financial statements. During June 2018, the Company closed two financing transactions that consisted of (i) $25.3&#xA0;million of net proceeds from the sale of 20,184,224 units (each a &#x201C;Unit&#x201D;, and collectively, the &#x201C;Units&#x201D;), with each Unit consisting of one share of the Company&#x2019;s common stock (&#x201C;Common Stock&#x201D;) and one warrant to purchase one share of Common Stock (each a &#x201C;Second Tranche Warrant&#x201D;, and collectively, the &#x201C;Second Tranche Warrants&#x201D;), to certain accredited investors on June&#xA0;25, 2018 (see Note 10) and (ii) $4.9&#xA0;million of net proceeds from an additional advance under its term loan facility on June&#xA0;26, 2018 (see Note 9). The Company had cash and cash equivalents of $38.8&#xA0;million at June&#xA0;30, 2018. The Company believes that its cash and cash equivalents at June&#xA0;30, 2018 and expected proceeds from existing collaboration agreements will enable the Company to maintain its current and planned operations (including continuation of its two Phase 3 clinical trials for YUTIQ) into the first quarter of calendar year 2019. In order to extend the Company&#x2019;s ability to fund its operations beyond then, including its planned U.S. commercial launch of DEXYCU and, if approved, YUTIQ, management&#x2019;s plans include obtaining additional equity financing from the potential exercise of the Warrants, from the sale of equity securities through an underwritten public offering or the sale of Common Stock through an&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">at-the-market</font></font>&#xA0;(&#x201C;ATM&#x201D;) program or from other sources and/or additional debt financing and/or, as applicable, reducing or deferring operating expenses. The timing and extent of the Company&#x2019;s implementation of these plans is expected to depend on the amount and timing of cash receipts from existing or any future collaborations or other agreements and/or proceeds from any financing transactions. There is no assurance that the Company will receive significant revenues from its planned commercialization of DEXYCU or, if approved, YUTIQ, or from its product license revenues under existing collaboration agreements, or that it will receive proceeds from the exercise of the Warrants.</p> </div>
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16888000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60671000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21907000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-53171000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
101000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000
CY2018 us-gaap Operating Expenses
OperatingExpenses
29235000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-26274000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
508000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1347000
CY2018 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
0
CY2018 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
16780000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41515000
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
20000000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
503000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
CY2018 us-gaap Profit Loss
ProfitLoss
-53171000
CY2018 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
0
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16178000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2961000
CY2018 us-gaap Sale Of Stock Description Of Transaction
SaleOfStockDescriptionOfTransaction
The Company closed two financing transactions that consisted of (i) $25.3 million of net proceeds from the sale of 20,184,224 units (“Units”), with each Unit consisting of one share of the Company’s common stock (“Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants”)
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2704000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47982000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
503000
CY2018 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1512000
CY2018 dei Trading Symbol
TradingSymbol
EYPT
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-27000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-159000
CY2016 us-gaap Depreciation
Depreciation
152000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340 pure
CY2016 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-20000
CY2016 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9013000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19780000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21702000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosure of assets and liabilities at the date of the consolidated financial statements and the reported amounts and disclosure of revenues and expenses during the reporting periods. Significant management estimates and assumptions include, among others, those related to revenue recognition for multiple-deliverable arrangements, recognition of expense in outsourced clinical trial agreements, realization of deferred tax assets and the valuation of stock option and other equity awards. Actual results could differ from these estimates.</p> </div>
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46226000 shares
CY2018 eypt Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
-15000
CY2018 eypt Finite Lived Intangible Assets Foreign Currency Translation Of Accumulated Amortization
FiniteLivedIntangibleAssetsForeignCurrencyTranslationOfAccumulatedAmortization
737000
CY2018 eypt Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-20000
CY2018 eypt Income Tax Reconciliation Change In Fair Value Of Derivative Liability
IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability
7227000
CY2018 eypt Amortization Of Debt Discount
AmortizationOfDebtDiscount
209000
CY2018 eypt Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
220000
CY2018 eypt Fair Value Of Warrants Issued With Debt
FairValueOfWarrantsIssuedWithDebt
355000
CY2018 eypt Fair Value Of Second Tranche Purchase Liability
FairValueOfSecondTranchePurchaseLiability
4734000
CY2018 eypt Warrants To Purchase Common Shares Expired
WarrantsToPurchaseCommonSharesExpired
623605 shares
CY2018 eypt Warrants Issued In Connection With Term Loan Facility
WarrantsIssuedInConnectionWithTermLoanFacility
486812 shares
CY2018 eypt Exercise Price Of Expired Warrants
ExercisePriceOfExpiredWarrants
2.50
CY2018 eypt Exercise Price Of Issued Warrants
ExercisePriceOfIssuedWarrants
1.23
CY2018 eypt Fair Value Of Second Tranche Warrants
FairValueOfSecondTrancheWarrants
18165000
CY2018 eypt Transaction Costs Allocated To Derivative Liabilities Expensed As Change In Fair Value Of Derivative
TransactionCostsAllocatedToDerivativeLiabilitiesExpensedAsChangeInFairValueOfDerivative
326000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2163000
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5605026 shares
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
87000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2163000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
756000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3808000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21640000
CY2016 us-gaap Interest Expense
InterestExpense
0
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1044000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1922000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-155000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
626000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-187000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7379000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
397000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
103000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6789000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
778000
CY2016 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-116000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
882000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1036000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2016 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
490000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13168000
CY2016 us-gaap Profit Loss
ProfitLoss
-21547000
CY2016 us-gaap Recognition Of Deferred Revenue
RecognitionOfDeferredRevenue
0
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14381000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
0
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4462000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16990000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16316000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-21547000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-93000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-96000
CY2016 us-gaap Operating Expenses
OperatingExpenses
23394000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-21774000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
485000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
17517000
CY2016 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16500000
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1620000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
2163000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16500000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
490000
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
0
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31623000 shares
CY2016 eypt Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
216000
CY2016 eypt Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
5000
CY2016 eypt Income Tax Reconciliation Change In Fair Value Of Derivative Liability
IncomeTaxReconciliationChangeInFairValueOfDerivativeLiability
0
CY2016 eypt Amortization Of Debt Discount
AmortizationOfDebtDiscount
0
CY2016 eypt Defined Contribution Plan Contributions By Employer
DefinedContributionPlanContributionsByEmployer
209000
CY2016 eypt Fair Value Of Warrants Issued With Debt
FairValueOfWarrantsIssuedWithDebt
0
CY2016 eypt Fair Value Of Second Tranche Purchase Liability
FairValueOfSecondTranchePurchaseLiability
0
CY2016 eypt Fair Value Of Second Tranche Warrants
FairValueOfSecondTrancheWarrants
0
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5140000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5160000
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
590000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34366000 shares
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6978000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4678000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
928000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45644000 shares
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-6116000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6136000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
701000
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38673000 shares
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2018Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1200000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-34428000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9782000
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
715000
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55387000 shares
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-5782000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5808000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
933000
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44530000 shares
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-7162000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7186000
CY2016Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
277000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34175000 shares
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-67000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-94000
CY2016Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5971000
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34177000 shares
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-5983000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6006000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
385000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39430000 shares

Files In Submission

Name View Source Status
0001193125-18-276414-index-headers.html Edgar Link pending
0001193125-18-276414-index.html Edgar Link pending
0001193125-18-276414.txt Edgar Link pending
0001193125-18-276414-xbrl.zip Edgar Link pending
d617568d10k.htm Edgar Link pending
d617568dex1012.htm Edgar Link pending
d617568dex1015.htm Edgar Link pending
d617568dex1019.htm Edgar Link pending
d617568dex1020.htm Edgar Link pending
d617568dex1024.htm Edgar Link pending
d617568dex1025.htm Edgar Link pending
d617568dex211.htm Edgar Link pending
d617568dex231.htm Edgar Link pending
d617568dex311.htm Edgar Link pending
d617568dex312.htm Edgar Link pending
d617568dex321.htm Edgar Link pending
d617568dex322.htm Edgar Link pending
d617568dex35.htm Edgar Link pending
eypt-20180630.xml Edgar Link completed
eypt-20180630.xsd Edgar Link pending
eypt-20180630_cal.xml Edgar Link unprocessable
eypt-20180630_def.xml Edgar Link unprocessable
eypt-20180630_lab.xml Edgar Link unprocessable
eypt-20180630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g617568fsnap1.jpg Edgar Link pending
g617568g31z94.jpg Edgar Link pending
g617568g59m36.jpg Edgar Link pending
g617568g60s42.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending